Select a medication above to begin.
Humira
adalimumab
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in patients w/ chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections incl. Legionella and Listeria observed; some infections have been fatal; most infections occur in combo w/ other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during adalimumab tx; initiate anti-TB tx before adalimumab tx; monitor for infection signs/symptoms during and after adalimumab tx; since active TB has developed in patients w/ negative tuberculin skin test, monitor all patients for active TB signs/symptoms; since histoplasmosis may be present in patients w/ negative antigen and antibody tests, consider empiric antifungal tx in patients w/ severe systemic illness if at risk for invasive fungal infection; D/C adalimumab tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated w/ TNF blockers; post-marketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) reported mostly in Crohn disease or ulcerative colitis patients, mostly adolescent and young adult males receiving concomitant azathioprine or mercaptopurine; uncertain whether HSTCL related to TNF-blocker monotherapy or in combo w/ other immunosuppressants
Adult Dosing .
Dosage forms: INJ (pen): 40 mg per 0.4 mL, 40 mg per 0.8 mL, 80 mg per 0.8 mL; INJ (pre-filled syringe): 10 mg per 0.1 mL, 10 mg per 0.2 mL, 20 mg per 0.2 mL, 20 mg per 0.4 mL, 40 mg per 0.4 mL, 40 mg per 0.8 mL, 80 mg per 0.8 mL; INJ (vial): 40 mg per 0.8 mL; convenience packs
Dosage Form Details
- [Crohn disease, UC, HS pen 4-wk starter pack]
- Info: 40 mg per 0.8 mL x6
- [Crohn disease, UC, HS pen 4-wk starter pack]
- Info: 80 mg per 0.8 mL x3
- [psoriasis or uveitis pen 5-wk starter pack]
- Info: 80 mg per 0.8 mL x1 and 40 mg per 0.4 mL x2
rheumatoid arthritis, moderate-severe
- [40 mg SC q2wk]
- Info: may incr. dose to 40 mg SC qwk or 80 mg SC q2wk if not on methotrexate
psoriatic arthritis
- [40 mg SC q2wk]
ankylosing spondylitis
- [40 mg SC q2wk]
Crohn disease, moderate-severe
- [40 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29
ulcerative colitis, moderate-severe
- [40 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29; Info: D/C if no evidence of remission after 8wk
psoriasis, moderate-severe chronic plaque
- [40 mg SC q2wk]
- Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8
hidradenitis suppurativa, moderate-severe
- [40 mg SC qwk or 80 mg SC q2wk]
- Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
uveitis
- [40 mg SC q2wk]
- Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8; Info: for non-infectious intermediate, posterior, and panuveitis
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (pen): 40 mg per 0.4 mL, 40 mg per 0.8 mL, 80 mg per 0.8 mL; INJ (pre-filled syringe): 10 mg per 0.1 mL, 10 mg per 0.2 mL, 20 mg per 0.2 mL, 20 mg per 0.4 mL, 40 mg per 0.4 mL, 40 mg per 0.8 mL, 80 mg per 0.8 mL; INJ (vial): 40 mg per 0.8 mL; convenience packs
Dosage Form Details
- [adolescent 30-59 kg HS pen 5-wk starter pack]
- Info: 80 mg per 0.8 mL x1 and 40 mg per 0.4 mL x2
- [peds 17-39 kg Crohn disease pre-filled syringe 4-wk starter pack]
- Info: 80 mg per 0.8 mL x1 and 40 mg per 0.4 mL x1
- [peds >40 kg Crohn disease pre-filled syringe 4-wk starter pack]
- Info: 80 mg per 0.8 mL x3
- [peds >40 kg UC pen 4-wk starter pack]
- Info: 80 mg per 0.8 mL x4
polyarticular juvenile idiopathic arthritis, moderate-severe
- [2 yo and older, 10-14 kg]
- Dose: 10 mg SC q2wk
- [2 yo and older, 15-29 kg]
- Dose: 20 mg SC q2wk
- [2 yo and older, >30 kg]
- Dose: 40 mg SC q2wk
Crohn disease, moderate-severe
- [6 yo and older, 17-39 kg]
- Dose: 20 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC x1 on day 15, then 20 mg SC q2wk on day 29
- [6 yo and older, >40 kg]
- Dose: 40 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC q2wk on day 29
ulcerative colitis, moderate-severe
- [5 yo and older, 20-39 kg]
- Dose: 20 mg SC qwk or 40 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC x1 on days 8 and 15, then 20 mg SC qwk or 40 mg SC q2wk on day 29
- [5 yo and older, >40 kg]
- Dose: 40 mg SC qwk or 80 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on days 8 and 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 8, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
hidradenitis suppurativa, moderate-severe
- [12 yo and older, 30-59 kg]
- Dose: 40 mg SC q2wk; Start: 80 mg SC x1 on day 1, then 40 mg SC q2wk on day 8
- [12 yo and older, >60 kg]
- Dose: 40 mg SC qwk or 80 mg SC q2wk; Start: 160 mg SC x1 on day 1, then 80 mg SC x1 on day 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29; Alt: start 80 mg SC x1 on days 1, 2, 15, then 40 mg SC qwk or 80 mg SC q2wk on day 29
uveitis
- [2 yo and older, 10-14 kg]
- Dose: 10 mg SC q2wk Info: for non-infectious intermediate, posterior, and panuveitis
- [2 yo and older, 15-29 kg]
- Dose: 20 mg SC q2wk; Info: for non-infectious intermediate, posterior, and panuveitis
- [2 yo and older, >30 kg]
- Dose: 40 mg SC q2wk; Info: for non-infectious intermediate, posterior, and panuveitis
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]